Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels MM Santoro, L Fabeni, D Armenia, C Alteri, D Di Pinto, F Forbici, A Bertoli, ... Clinical infectious diseases 58 (8), 1156-1164, 2014 | 83 | 2014 |
Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs G Berno, M Zaccarelli, C Gori, M Tempestilli, A Antinori, CF Perno, ... BMC medical genetics 15, 1-7, 2014 | 32 | 2014 |
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia D Armenia, L Fabeni, C Alteri, D Di Pinto, D Di Carlo, A Bertoli, C Gori, ... Journal of Antimicrobial Chemotherapy 70 (6), 1865-1873, 2015 | 28 | 2015 |
Comparative evaluation of subtyping tools for surveillance of newly emerging HIV-1 strains L Fabeni, G Berno, J Fokam, A Bertoli, C Alteri, C Gori, F Forbici, D Takou, ... Journal of Clinical Microbiology 55 (9), 2827-2837, 2017 | 26 | 2017 |
SARS-CoV-2 variants identification: overview of molecular existing methods G Berno, L Fabeni, G Matusali, CEM Gruber, M Rueca, E Giombini, ... Pathogens 11 (9), 1058, 2022 | 25 | 2022 |
Interferon-α improves phosphoantigen-induced Vγ9Vδ2 T-cells interferon-γ production during chronic HCV infection E Cimini, C Bonnafous, V Bordoni, E Lalle, H Sicard, A Sacchi, G Berno, ... PloS one 7 (5), e37014, 2012 | 25 | 2012 |
Virological characterization of the first 2 COVID-19 patients diagnosed in Italy: phylogenetic analysis, virus shedding profile from different body sites, and antibody response … F Colavita, D Lapa, F Carletti, E Lalle, F Messina, M Rueca, G Matusali, ... Open Forum Infectious Diseases 7 (10), ofaa403, 2020 | 21 | 2020 |
Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients C Agrati, C Gioia, C Castilletti, D Lapa, G Berno, V Puro, F Carletti, ... AIDS research and human retroviruses 28 (12), 1606-1616, 2012 | 19 | 2012 |
Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control R Salpini, M Alkhatib, G Costa, L Piermatteo, FA Ambrosio, VC Di Maio, ... Journal of Antimicrobial Chemotherapy 76 (2), 396-412, 2021 | 17 | 2021 |
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single … D Armenia, D Di Carlo, A Calcagno, G Vendemiati, F Forbici, A Bertoli, ... Journal of Antimicrobial Chemotherapy 72 (3), 855-865, 2017 | 16 | 2017 |
Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir Y Bouba, G Berno, L Fabeni, L Carioti, R Salpini, S Aquaro, V Svicher, ... Journal of Antimicrobial Chemotherapy 75 (7), 1778-1786, 2020 | 15 | 2020 |
Potential implications of CYP3A4, CYP3A5 and MDR‐1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV‐1 patients G Berno, M Zaccarelli, C Gori, M Tempestilli, L Pucci, A Antinori, CF Perno, ... Journal of the International AIDS Society 17, 19589, 2014 | 15 | 2014 |
Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy L Fabeni, C Alteri, G Berno, R Scutari, N Orchi, G De Carli, A Bertoli, ... Sexually Transmitted Infections 95 (8), 619-625, 2019 | 14 | 2019 |
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical … D Armenia, F Forbici, A Bertoli, G Berno, V Malagnino, R Gagliardini, ... Journal of Global Antimicrobial Resistance 30, 326-334, 2022 | 10 | 2022 |
Virological response and resistance profile in highly treatment‐experienced HIV‐1‐infected patients switching to dolutegravir plus boosted darunavir in clinical practice D Armenia, Y Bouba, R Gagliardini, L Fabeni, V Borghi, G Berno, ... HIV medicine 22 (6), 519-525, 2021 | 9 | 2021 |
Virological and serological characterisation of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination between December 2020 and March 2021 F Colavita, S Meschi, CEM Gruber, M Rueca, F Vairo, G Matusali, D Lapa, ... Frontiers in Medicine 8, 815870, 2022 | 8 | 2022 |
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia L Fabeni, G Berno, V Svicher, F Ceccherini-Silberstein, C Gori, A Bertoli, ... Journal of clinical microbiology 53 (9), 2935-2941, 2015 | 8 | 2015 |
Rapid and qualitative identification of SARS-CoV-2 mutations associated with variants of concern using a multiplex RT-PCR assay coupled with melting analysis G Sberna, L Fabeni, G Berno, F Carletti, E Specchiarello, F Colavita, ... International Journal of Infectious Diseases 122, 401-404, 2022 | 5 | 2022 |
Interferon-a improves phosphoantigen-induced Vg9Vd2 T-cells interferon-g production during chronic HCV infection E Cimini, C Bonnafous, V Bordoni, E Lalle, H Sicard, A Sacchi, G Berno, ... PLoS One 7, e37014, 2012 | 5 | 2012 |
Molecular transmission dynamics of primary HIV infections in Lazio Region, years 2013–2020 L Fabeni, G Rozera, G Berno, E Giombini, C Gori, N Orchi, G De Carli, ... Viruses 13 (2), 176, 2021 | 3 | 2021 |